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Objective: The European Society on Clinical and Economic aspects of Osteoporosis and Osteoarthritis
(ESCEO) organised a working group to evaluate the need for updating the current European guideline on
clinical investigation of drugs used in the treatment of osteoarthritis (OA).
Design: Areas of potential attention were identified and the need for modifications, update or clarifi-
cation was examined. Proposals were then developed based on literature reviews and through a
consensus process.
Results: It was agreed that the current guideline overall still reflects the current knowledge in OA,
although two possible modifications were identified. The first relates to the number and timing of
measurements required as primary endpoints during clinical trials of symptom-relieving drugs, either
drugs with rapid onset of action or slow acting drugs. The suggested modifications are intended to take
into consideration the time related clinical need and expected time response to these drugs e i.e., a more
early effect for the first category in addition to the maintenance of effect, a more continuous benefit over
the long-term for the latter e in the timing of assessments.
Secondly, values above which a benefit over placebo should be considered clinically relevant were
considered. Based on literature reviews, the most consensual values were determined for primary
endpoints of both symptom-relieving drugs (i.e., pain intensity on a visual analogue scale (VAS)) and
disease-modifying drugs (i.e., radiographic joint-space narrowing).J.-Y. Reginster, Department of
University of Liege, CHU Sart
er).
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future update of the guideline for the registration of drugs in OA.
© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Osteoarthritis (OA) is a common, slowly progressive condition
that may affect all joint structures, and is a major cause of pain and
chronic disability in the elderly1. Current treatment includes non-
pharmacological and pharmacological therapies that are taken
into account in a recent algorithm developed to advise on the
possible stepwise approach to the sequence of interventions2.
Symptomatic drugs are usually divided into drugs with a rapid
onset of action such as paracetamol or other analgesics and non-
steroidal anti-inflammatory drugs (NSAIDs) e (being either non-
selective or selective COX-2 inhibitors) e or intra-articular in-
jections of corticosteroids, and Symptomatic Slow Acting Drugs for
OA (SYSADOAs) such as glucosamine and chondroitin sulfate or
intraarticular hyaluronic acid. Drugs with potential beneficial effect
on the joint structure (Disease Modifying OsteoArthritis Drugs,
DMOADs) may be developed in the future: these may or may not
have a direct effect on symptoms and they may delay the disease
process, as preliminarily suggested by currently available SYSA-
DOAs showing some hints of modification of joint structure3,4,5.
A first European regulatory document aimed at providing advice
for the development of drugs in OA was issued in 19986. The latest
version of the Committee for Medicinal Products for Human Use
(CHMP)/European Medicines Agency (EMA) guidance7, adopted in
2010, is a revision of that document.
The first version of the guideline6 was derived from a report by
the Group for Respect of Ethics and Excellence in Sciences (GREES)8.
This group has been thereafter providing recommendations for an
update based on a critical analysis of the available science9e11.
A substantial part of these proposals were taken into account in
the 2010 current version of the CHMP/EMA guidance7.
Several elements of the guideline are the subject of much
debate. They are mainly related to the cut-off values that should
define a clinically relevant symptomatic or structural improvement
and to the timing of assessments that should be collected
throughout confirmatory clinical trials.
For this reason, under the auspices of the European Society on
Clinical and Economic aspects of Osteoporosis and Osteoarthritis
(ESCEO), a special section of the GREES was convened in May 2014
to discuss these issues in the light of recent data and expert opinion.
The consensus view, which might be possibly considered in future
guidelines, is presented in this discussion paper.
Methods
As in previous initiatives and publications, the GREES/ESCEO
working group consisted of clinical scientists expert in the field of OA
in academia and consulting for drug development within the phar-
maceutical industry, and representatives of national or European
licensing authorities giving their contribution on a personal basis.
As a general methodology, the group reviewed the current
version of the CHMP/EMA guideline in detail7.
The members of the working group were asked to assess the
possible need for revision of the guideline in view of their knowl-
edge of the field and of the clinical literature, in order to identify the
areas of potential attention. The group judged that there was no
need to revise any of the first four sections within the CHMP/EMAJ-Y, et al., Recommendations
the treatment of osteoarthri
tilage (2015), http://dx.doi.odocument (including disease definition, drug categories and pa-
tient selection). Conversely, there was general consensus that
specific parts within the methods for assessing efficacy section
(Section 5) for both symptom modifying and structure modifying
drugs, with particular respect to the clinical relevance of the
changes on the primary endpoint(s) and the timing of assessment,
may be in need of clarification. This would inevitably affect also the
section on the design of the studies (Section 6.2) with particular
regard to confirmatory trials, while the guideline sections on ‘early
studies in man’ (Section 6.1) or the ‘clinical safety evaluation’
(Section 7) were not explicitly covered by the discussion.
Members of the group (SR, OB and GH-B) were therefore asked
to prepare a full review of the literature on these topics and to
present the results at the May 2014 meeting. After the pre-
sentations, a comprehensive discussion was hold within the group
and shared conclusions were reached.
Results
Table I summarizes the proposed changes to the current
guideline document, as extensively reported below.
Primary endpoint and design of clinical studies of symptom
modifying drugs
Symptom modifying drugs act on pain and potentially on
functional disability. According to the CHMP guideline, Phase III
pivotal studies should have a randomised, double-blind, parallel
group design. A three-arm study with placebo and a most appro-
priate active comparator is recommended for symptom modifying
drugs: the nature of the active comparator can be discussed be-
tween the regulatory authority and the sponsor e.g., in a scientific
advice procedure. Long-term efficacy data (e.g., on an open label
extension) as well as data after stopping therapy should be pro-
vided. Importantly, the absence of deleterious effects on joint
structure should be established from imaging (e.g., radiographic)
data obtained over at least one year.
The recommended primary endpoint for clinical development of
symptom modifying drugs is pain attributable to the target joint.
Pain referring to a recent period, ideally the past 24 or 48 h, should
be self-assessed by the patient using a validated method (e.g., the
visual analogue scale-VAS, Likert scale…). Validated multidimen-
sional tools with pain subscale index are also acceptable. Functional
disability may be considered as an important co-primary endpoint,
again with validated disease-specific and joint-specific in-
struments. However, if functional disability is not a co-primary
endpoint and benefit is only shown for pain, at least the absence
of deterioration of physical function should be demonstrated.
In the opinion of the working group, some specific clarifications
and recommendations were considered necessary and are given
below for the development of drugs with rapid onset of actions and
SYSADOAs, respectively.
Symptom modifying drugs with rapid onset of action
The current guideline recommends that the primary endpoint,
i.e., the change from baseline in pain intensity and optionallyfor an update of the 2010 European regulatory guideline on clinical
tis and reflections about related clinically relevant outcomes: expert
rg/10.1016/j.joca.2015.07.001
Table I
Proposedmodifications to the current CHMP/EMA guideline on the clinical investigation of medicinal products used in the treatment of OA (CPMP/EWP/784/97). Sections 1e4
and 7 do not require modifications
Current content Proposed modification
5. Methods to assess efficacy
5.1 Medicinal products intended to improve symptoms
Primary endpoint
 Pain attributable to the target joint is the primary endpoint.  Unchanged
 Pain self-assessment by a validatedmethod (e.g., VAS, NRS, Likert) separately on
motion at rest, or validatedmultidimensional tools subscale index, referring to a
recent past (e.g., 24e48 h), as absolute difference vs baseline.
 Unchanged
 The difference vs placebo should be predefined and justified based on published
trials.
 A rounded MPCI 10 mm average value on a 100 mm VAS is acceptable as
threshold for clinically significant difference vs placebo at the patient group
level.
 Functional disability co-primary optionally, or at least show no deterioration.  Unchanged
Secondary endpoints
 Course of pain intensity (e.g., AUC).  Unchanged
 Percentage of responders per predefined definition (including PASS, MCII,
OARSI criteria).
 Responder criteria are important at the individual patient level: MCII is the
preferred concept and PASS is helpful for assessing maintenance of
improvement; OARSI/OMERACT criteria as alternative, but do not distinguish
between pain and function. Clinically relevant improvement at a 10e20%
difference vs placebo depending on drug class (SYSADOA and symptomatic
drugs with rapid onset of action, respectively).
 Other secondary endpoints  Unchanged
5.2 Medicinal products intended to slow or prevent structural damage
 Radiographic JSN as primary endpoint, with technical recommendations for
assessment.
 Unchanged
 MRI as potential alternative surrogate endpoint still subject to validation,
similarly to biochemical markers.
 Watch out for ongoing initiatives to qualify biochemical markers and
especially MRI as an imaging biomarker offering surrogacy over shorter
periods and in smaller trials than with JSN.
6. Strategy and design of clinical trials
6.1 Early studies in Man  Unchanged
6.2 Therapeutic confirmatory studies
6.2.1 Study design
Modification of symptoms
 Studies should have randomized, double-blind, three-arm (placebo and active
comparator) design.
 Unchanged
 Primary efficacy endpoint at a time-point showing maximum effect vs placebo,
with maintenance confirmed for at least 3 months, for symptom modifying
drugs with rapid onset of action.
 Most trials powered for primary endpoint significance vs placebo at 12e13
weeks, but several patients may need very short-term pain relief (2e4
weeks).
 Three classes among drugs with rapid onset of action: a) very short-term pain
relief, primary endpoint at 2e4 weeks (no worsening at 12 weeks); b) both
very short-term andmaintenance of pain relief, co-primary end-points at 2e4
and 12 weeks (issues in powering the studies); c) relief of persistent pain,
primary endpoint at 12 weeks (effects at 2e4 weeks should be described).
 For SYSADOA, evaluation after at least 6e12 months.  Pain intensity at multiple time-points, at least two consecutive assessments
(4 weeks apart) or 50% of the assessments (including the last one in either
case), over 6e12 months.
 Structural changes to be monitored for at least one year to exclude deleterious
effects on the joint.
 Unchanged
 Data after stopping therapy should be obtained.  Unchanged
Modification of structure
 Studies should have randomized, double-blind, parallel group design, not
shorter than 2 years
 Unchanged
 Clinical endpoints, e.g., time to virtual or actual joint replacement, preferable. If
structural changes (JSN) are primary endpoint, magnitude of clinically relevant
effect should be predetermined.
 Radiographic JSN 0.5 mm corresponds to the lowest difference exceeding
the measurement error and is a relevant threshold to demonstrate activity
at the individual patient level, in that significantly correlates with recourse to
TJR in several studies. At the patient group level, these studies have shown
that the mean reduction in JSN ranges from 0.10 to 0.36 mm vs placebo over 2
e3 years.
6.2.2 Choice of control  Unchanged
6.2.3 Concomitant interventions  Unchanged
Abbreviations: NRS ¼ Numeric Rating Scale; AUC ¼ Area Under the Curve; MCII ¼Minimum Clinically Important Improvement; SYSADOA ¼ Symptomatic Slow Acting Drugs
in Osteoarthritis; TJR ¼ Total Joint Replacement.
J.-Y. Reginster et al. / Osteoarthritis and Cartilage xxx (2015) 1e8 3functional disability, should be assessed at a time-point appropriate
to show the maximum effect over placebo. However, the guideline
adds that the maintenance of effect should be evaluated after at
least 3 months. Consequently, most clinical trials aiming at
demonstrating the benefit of drugs rapidly acting on symptoms of
OA are powered to reach statistical significance for the comparison
of the drug vs placebo at 12 or 13 weeks only12e16.
Although OA is a chronic disease, it shows fluctuating levels of
pain over time. For this reason, heterogeneous results for non-Please cite this article in press as: Reginster J-Y, et al., Recommendations
investigation of medicinal products used in the treatment of osteoarthri
consensus statement, Osteoarthritis and Cartilage (2015), http://dx.doi.orselective or COX-2 selective inhibitors NSAIDs have been shown
in clinical trials17 and several studies have failed to show clinically
relevant outcomes measured at 3 months18,19. Moreover, from the
patient's perspective it would seem appropriate to have different
therapeutic options, including a treatment with a demonstrated
acute analgesic effect in addition to maintenance of improvement.
In systematic reviews of randomised clinical trials in knee OA
patients and as acknowledged by the current CHMP guideline, the
time-point of maximum effect over placebo was determined to befor an update of the 2010 European regulatory guideline on clinical
tis and reflections about related clinically relevant outcomes: expert
g/10.1016/j.joca.2015.07.001
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intra-articular steroids injections and topical NSAIDs, respec-
tively17,20. Indeed, these drug classes are intended to rapidly
decrease pain/inflammation during the symptomatic phases of OA.
Furthermore, in clinical trials, the possibility of detecting a
symptomatic benefit over placebo is more likely early in the course
of the study than at 3 months, due to the self-healing effect: in OA
clinical trials, placebo responses on pain have been shown to be
considerable21,22 and may increase over time23. Last but not least,
several patients may actually need drugs that provide very short-
term pain relief. Therefore, the clinical relevance of this time-
point at 3 months appears questionable for this class of drugs,
especially for those with a particularly fast and relevant onset of
action, that in several instances may even better serve patient's
needs. Thus, the group felt it may be at least as important to
demonstrate a decrease in pain intensity in the first weeks of
treatment as it is after 3 months, as long as the characteristics of the
new drug indicate that this is a potentially achievable target. Two to
4weeks appear as a reasonable target for the demonstration of pain
reduction, depending on the drug tested.
Theworking group proposal is that the benefit of most analgesic
drugs over placebo on pain assessed at 2e4 weeks after the initi-
ation of treatment might be considered an alternative primary
endpoint. The currently recommended benefit at 3 months may
remain a co-primary endpoint as evidence for the maintenance of
the effect of the drug, or in exceptional cases even as a secondary
endpoint if appropriately justified (e.g., depending on the indica-
tion claimed, or the characteristics of the drug and keeping in mind
that the extent of the difference between groups may be smaller at
3months than at 2e4 weeks for the reasons above, thus with issues
in appropriately powering the studies).
Drugs whose mechanism of action suggests a strong mainte-
nance of effects, may retain the currently recommended primary
endpoint at 3 months (but the effects after 2e4 weeks should be
described). In such a way, there may be three classes within
symptom modifying drugs with rapid onset of action: a) those that
provide very short-term pain relief, with trial primary endpoint
after 2e4 weeks (and at least no worsening over placebo on 12-
week data collected as secondary endpoint); b) those providing
both very short-term pain relief and maintenance of such effect
after 12 weeks (two co-primary endpoints); c) those whose pri-
mary endpoint for pain relief is at 12 weeks, as currently recom-
mended (but whose effects after 2e4 weeks should be described).
Appropriate classification should be reflected in the drug labelling.
OA pain intensity should be measured by patient's self-
assessment with validated methods such as the Visual Analogue
Scale (VAS), which is enough sensitive to distinguish small differ-
ences. The guideline requires the demonstration of a statistically
significant and a clinically meaningful superiority vs placebo on
pain intensity to justify efficacy. However, there is no further
indication of where this clinically relevant superiority threshold
should be set at a patient group level or at an individual patient
level.
At the patient group level, the Minimum Perceptible Clinical
Improvement (MPCI) could be considered: a value of 9.7 mm on the
100 mm normalised pain subscale of a multidimensional tool such
as the WOMAC (Western Ontario and McMaster Universities) in-
dex24 (a copyrighted instrument, therefore not publicly available)
has been shown to represent the MPCI in patients with knee or hip
OA25. Thus, a rounded 10 mm value on a 100 mm pain VAS is
accepted by the scientific community as a threshold for a clinically
significant difference as compared with placebo26. Indeed, it has
been shown to be an achievable target for symptom modifying
drugs with rapid onset of action, e.g., NSAIDs at the peak of their
effects after 2e4 weeks of treatment20. Such threshold may be usedPlease cite this article in press as: Reginster J-Y, et al., Recommendations
investigation of medicinal products used in the treatment of osteoarthri
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calculation. Clearly, the final decision on product approval will
depend on the overall assessment of the benefit and harm related
to the new specific agent.
At the individual patient level, the most widely accepted and
preferred concept to define a responder is the Minimal Clinically
Important Improvement (MCII, i.e., “feeling better”)27,28. A
responder rate based on the MCII could be chosen as an important
secondary endpoint. Also, the Patient Acceptable Symptom State
(PASS, i.e., “feeling good”) could be used to calculate the rate of
responders29 especially when assessing maintenance of improve-
ment after 3 months. Another method for determining a clinically
relevant responder would be to use the OARSI/OMERACT responder
criteria30. However, they cannot distinguish between pain and
function.
The difference between the rates (percentages) of defined re-
sponders between test and placebo group should show a relevant
clinical benefit for a substantial part of treated patients to justify
the treatment. Such difference should be pre-determined and at
least approximately 20% over placebo.
Further improvement of study design could be reached by
requiring a flaring design in knee OA patients31 and considering the
documented differences in the outcome between knee and hip OA
by assessing the locations separately19.
SYSADOAs
The current guideline recommends that for SYSADOAs the pri-
mary endpoint for symptoms should be assessed after at least 6e12
months of treatment. It is unclear whether the extent of improve-
ment after such a long treatment course should be similar to that
suggested for rapidly acting symptomatic agents and whether a
single assessment at the end of treatment is sufficient.
With respect to the latter, the position of the working groupwas
that the assessment of pain intensity at multiple time-points,
reflecting a sustained clinical benefit, would be more appropriate
and relevant for this class of drugs than a rather random outcome
measurement of improvement at only one single time point.
Insofar as OA may be associated with remitting and relapsing
symptoms, intermediate measurements should be taken into ac-
count in the evaluation of slow-acting drugs, as well as consistency
between various assessments.
This statement is in accordance with data showing that the
consistency of pain at two time points, not only its severity, can
predict the need for total knee replacement32. The association was
consistent across each level of pain severity. In line with this
concept of consistency between multiple measurements, the sus-
tainability and persistence of symptoms were considered impor-
tant components for “virtual joint replacement” (VJR), a composite
index proposed as a surrogate outcome for OA progression in
clinical trials33.
The multiplicity of assessments however raised several issues,
including the questions of the number of measurements and when
they should be performed. In 6e12-month clinical trials, the
number of assessments of pain and function is generally from 3 to
6, distributed over the treatment period in the most appropriate
manner according to the characteristics of the medicinal product
and of the trial.
The group suggested that within the context of confirmatory
trials for SYSADOAs, a statistically significant improvement should
be detected at least on the last two consecutive assessments as long
as they are sufficiently spaced, e.g., not less than 4 weeks apart.
Alternatively, a significant improvement might be seen on at least
50% of the assessments including the last one. In any case, there
should be no clinically relevant worsening at any of the time points.for an update of the 2010 European regulatory guideline on clinical
tis and reflections about related clinically relevant outcomes: expert
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the results is that themultiplicity of measurements should be taken
into consideration in the preparation of the statistical analysis
plan34.
Also for SYSADOAs, the current CHMP-guideline recommends
that the mean difference in the change in pain intensity vs placebo
should be statistically significant and clinically relevant. It is
generally admitted that the expected extent of improvement is
smaller with SYSADOAs than with drugs with rapid onset of ac-
tion35,36. Published clinical trials show symptomatic improvement
in the 5e6 mm range on a 100 mm VAS3742. Average changes in
this range translated in a clinically relevant higher proportion of
responder patients according to MCII, PASS, or OARSI/OMERACT
criteria. The working group suggested at least 5 mm as a clinically
relevant threshold for a SYSDAOA in the difference with placebo at
the patient group level, also considering that the required sustained
benefit might increase the precision of measurements (see above),
that such an effect would allow the control of the disease symp-
toms over much longer treatments and finally, in view of the
generally better safety of SYSADOAs compared with faster acting
medications. At the individual patient level, the same parameters
considered for symptommodifying drugswith rapid onset of action
should be used for calculating responder rates, aiming at a differ-
encewith placebo in the 10e20% range as suggested in pivotal trials
of existing SYSADOA42.
Primary endpoint and design of Disease Modifying Drugs for
Osteoarthritis (DMOADs)
Structural modification of the joint is considered to be the most
important determinant of disease progression. Joint Space Nar-
rowing (JSN),measured on conventional X rays, is currently the only
validated primary outcome measure to show progression of OA7,43.
The surrogacy of JSN has been established in 8-year studies where it
has been shown to correlate with the need for joint replacement in
knee OA44,45. It is assumed that this could also be valid for hip OA.
Theworking group agrees therefore on the current guideline stating
that radiographic JSN is an acceptable surrogate outcome measure
for OA disease modification and is still the gold standard compared
with othermethods includingmagnetic resonance imaging (MRI) or
biochemicalmarkers. The group also agrees on the current technical
recommendations within the guideline for appropriate radiological
assessment. However, if a clear consensus admits that JSN is the
most appropriate structural measure46,47, a threshold value above
which a reduction of JSN should be considered as clinically relevant
has not been validated. Nevertheless, a minimum radiographic JSN
of 0.5 mm or more over the duration of the trial (i.e., 2e3 years) in
the individual patient has been suggested to be a relevant threshold
to demonstrate efficacy26,48. This value corresponds mostly to the
lowest difference in joint space width exceeding the measurement
error: while, pragmatically, the measurement error should be
study-specific, the current guidelines state that the magnitude of
the drug effect should be predetermined based on previously
established findings. The group agrees on this statement (also in
view of the need of predetermining the sample size of the trial) and
it appears therefore logical to base the choice on the available
literature. In this respect and notably, patients with radiographic
minimum JSN 0.5 mm over 3 years have a statistically significant,
three-to fourfold increase in risk of joint replacement over up to 8
years11,44,. However, none of the considered thresholds of mean JSN
(0.2e0.8 mm) was significantly related to the clinical outcome. In a
number of studies, individual patients considered having a clinically
relevant radiographic progression are those with a minimum JSN
0.5 mm5,4852. Conversely, it is more difficult to determine what
should be a clinically relevant difference in JSN at a patient groupPlease cite this article in press as: Reginster J-Y, et al., Recommendations
investigation of medicinal products used in the treatment of osteoarthri
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period of observation, and since the distribution of radiographic
joint space changes does not follow a Normal law. Published clinical
trials generally show a group mean reduction of JSN with glucos-
amine3,4,50, chondroitin sulfate5,50,53 or strontium ranelate49
ranging from less than 0.10 to 0.36 mm over 2 or 3 years. Such
average changes are clinically relevant in that they seem to predict
total joint replacement over longer periods of observation54. As
discussed above for SYSADOA pain relief assessments, the consis-
tency of the trend of JSN over the duration of the trial could be
important to consider, as it has been shown that taking into account
more measurements and not only the last one, may be more rele-
vant as a predictive tool of future knee surgery in the individual
patient.44
While radiographic JSN is the currently accepted primary
endpoint at the regulatory level for a DMOAD, it is acknowledged
that it is an imperfect surrogate of disease progression. First of all, it
may reflect modifications in other structures, e.g., meniscal extru-
sion and degeneration, while not addressing changes at other joint
tissues, e.g., synovitis or bone marrow lesions. In addition, small
sensitivity to change may require several hundred patients in 2e3
year trials to show relevant changes over placebo. For this reason
initiatives are in progress such as the one by the Foundation for NIH
OA Biomarkers Consortium55 to qualify new biochemical or imag-
ing biomarkers that may be predictive of radiographic (and pain)
progression over shorter treatment periods and in smaller scale
trials. In particular, MRI may become the imaging modality of
choice in the future if its validity and responsiveness is proven. MRI
measures currently investigated include quantitative cartilage
morphometry, bone marrow lesions and other joint structure
changes on semi-quantitative analysis, bone shape/attrition and
subchondral bone area55.
Discussion
The current CHMP European guidance on clinical investigation
of drugs for the treatment of OA overall is still in line with the
current scientific knowledge and only a few points that deserve
discussion were identified. They mainly relate to the number and
timing of measurements of the primary endpoints performed
during clinical trials with symptom modifying medicinal products
with rapid onset of effect and SYSADOA, and the need to define
more precisely the required clinically relevant benefit thresholds
for both symptom modifying and structure modifying agents.
For symptom-relieving drugs, the guideline recommends that
an improvement in pain intensity should be demonstrated pri-
marily at 3 months for drugs with rapid onset of action and at 6
months or 12 months for SYSADOAs. The suggested modifications
are intended to take into account the expected time-related main
clinical need and time response of these drugs e i.e., a more acute
effect for the first class of drugs in addition tomaintenance of effect,
a more sustained effect for the lattere in the timing of assessments.
For drugs providing very short-term pain relief, symptomatic
benefit should be demonstrated as primary endpoint after 2e4
weeks of treatment, to be possibly adapted to the pharmacokinetic
and pharmacodynamic characteristics of the drug tested, with the
maintenance of efficacy after a 3-month treatment period as a co-
primary endpoint or as a secondary endpoint if appropriately
justified. In the important subset of patients with persistent pain,
the primary endpoint should continue to be collected at 3 months,
thus giving preference to maintenance of effects. The exact product
characteristics should be described in the drug labelling. As dif-
ferences in the extent of pain reduction between knee and hip OA
patients are identified this should be considered by appropriately
assessing these patients separately.for an update of the 2010 European regulatory guideline on clinical
tis and reflections about related clinically relevant outcomes: expert
g/10.1016/j.joca.2015.07.001
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time points to better show sustained benefit. Significant benefit
over placebo should be shown on at least two consecutive assess-
ments including the last one over a 6e12-month treatment, or 50%
of the assessments including the last one with no clinically relevant
worsening at any time point.
A second aspect of the discussions concerned the threshold
value above which a benefit over placebo should be considered as
clinically relevant. Although none of the proposed thresholds is
officially validated and further confirmatory data are needed, the
most consensual values based on a literature reviewwere identified
for each class of drugs. For symptomatic drugs, the mean difference
of changes in pain intensity between the active drug and placebo at
the patient group level should be at least 10 mm on a 100 mm VAS
or on the normalised pain subscale of an appropriate multidi-
mensional tool (e.g., the WOMAC index) for a drug with a rapid
onset of action. For a SYSADOA such average difference should be at
least 5 mm, but it should be shown at repeated time points. At the
individual patient level, several responder criteria have been pro-
posed as secondary endpoints, including preferentially the MCII, or
the PASS (especially for documenting maintenance of effects), or
the OARSI/OMERACT criteria. The difference with placebo in
responder rate should be between 10% and 20% depending on the
drug class (SYSADOA or rapid onset of action, respectively). For
DMOADs, the reduction in the proportion of patients with radio-
graphic minimum JSN of more than 0.5mm over the duration of the
trial is suggested as a relevant threshold to demonstrate efficacy at
the individual patient level. Conversely, it is more difficult to pro-
pose an average difference with placebo in the change from base-
line at the patient group level, although available trials3,4,5,49,50,53
show that this may range from less than 0.10 to 0.36 mm over
2e3 years and be clinically relevant54. New initiatives are ongoing55
that may establish MRI as a better surrogate of OA progression.
Much remains to be established in OA. The research agenda
includes better understanding of underlying mechanisms of the
disease, and consensus on the definition of clinical outcomes.
Author's contribution
OB, JYR organized the meeting. SR, OB, GHB performed the
literature review. All authors have taken part in the discussion and
meeting and have critically analysed and approved the final
manuscript.
Competing interests
All authors have completed the International Committee of Medical
Journal Editors (ICMJE) uniform disclosure form at http://www.
icmje.org/coi_disclosure.pdf.
Pr. Branco, Pr. Maggi declared having no conflicts of interests.
Pr. Reginster has received consultancy fees from Servier,
Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche,
Merckle, Nycomed, NPS, Theramex, UCB, grants from Bristol Myers
Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Lilly, Novartis,
Roche, GlaxoSmithKline, Amgen, Servier, and lecture fees from
Merck Sharp& Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis,
Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma,
Zodiac, Analis, Theramex, Nycomed, Novo-Nordisk, Nolver.
Dr Reiter: has received reimbursement for travel expenses from
the ESCEO and lecture fees from Gedel Congress Management
GmbH.
Pr. Bruyere has received grants from IBSA, MSD, Novartis,
Nutraveris, Pfizer, Rottapharm, Servier, SMB, Theramex, consul-
tancy fees from Bayer, Genevrier, IBSA, Rottapharm, Servier, SMB
and reimbursement for travel expenses from IBSA, MSD, Novartis,
Pfizer, Rottapharm, Servier, Theramex.Please cite this article in press as: Reginster J-Y, et al., Recommendations
investigation of medicinal products used in the treatment of osteoarthri
consensus statement, Osteoarthritis and Cartilage (2015), http://dx.doi.oPr. Berenbaum has received board membership fees from
Pfizer, AbbVie, Servier, Expanscience, Sanofi, Novartis, consultancy
fees from Janssen, grants from TRB Chemedica, Pierre Fabre,
Expanscience, lecture fees from Servier, Expanscience, TRB Chem-
edica, IBSA and reimbursement for travel expenses from the ESCEO
and Pfizer.
Pr. Brandi has received board membership fees from Alexion
and Servier, grants from Servier, MSD, Eli Lilly, Amgen, NPS, SPA,
Abiogen, Bruno Farmaceutici, Alexion, Shire, consultancy fees from
Servier, MSD, Amgen, NPS, SPA, Abiogen, Alexion, Shire, and lecture
fees from NPS and Bruno Farmaceutici.
Pr. Devogelaer has received reimbursement for travel expenses
from the ESCEO.
Pr. Herrero Beaumont has received reimbursement for travel
expenses from the ESCEO.
Pr. Kanis has received grants from Amgen, Lilly, Medtronic,
Novartis, Pfizer, Sanofi-Aventis, Servier, Warner-Chilcott, and per-
sonal fees from AgNovos Healthcare USA, Amgen, D3A, Lilly, Med-
imaps, Unigene, Pfizer, Servier, and non-financial support from
Asahi.
Pr. Maheu has received board membership fees from Bioventus,
consultancy fees from Pierre Fabre Labs, Expanscience Labs, Rot-
tapharm France, grants from Servier, lecture fees from Expan-
science Labs and Rottapharm.
Pr. Richette has received board membership fees from Gen-
evrier, Servier, lecture fees fromGenevrier, Servier, Fidia, BioIberica,
Expanscience, Rottapharm, Sanofi.
Pr. Rizzoli has received board membership fees from Amgen,
Danone, Servier, MSD, consultancy fees from Danone and lecture
fees from Amgen, Danone, Servier, MSD, GSK.
Pr. Cooper has received consultancy, lecture fees, and honoraria
from Amgen, GSK, Alliance for Better Bone Health, MSD, Eli Lilly,
Pfizer, Novartis, Servier, Merck, Medtronic, Roche.Acknowledgements
This meeting was founded by the European Society for Clinical
and Economics Aspect of Osteoporosis and Osteoarthritis, a non for
profit organization from Belgium.References
1. Ethgen O, Reginster JY. Degenerative musculoskeletal disease.
Ann Rheum Dis 2004;63:1e3.
2. Bruyere O, Cooper C, Pelletier JP, Branco J, Luisa BM,
Guillemin F, et al. An algorithm recommendation for the
management of knee osteoarthritis in Europe and interna-
tionally: a report from a task force of the European Society for
Clinical and Economic Aspects of Osteoporosis and Osteoar-
thritis (ESCEO). Semin Arthritis Rheum 2014;44:253e63.
3. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O,
et al. Long-term effects of glucosamine sulphate on osteoar-
thritis progression: a randomised, placebo-controlled clinical
trial. Lancet 2001;357:251e6.
4. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G,
Rovati LC. Glucosamine sulfate use and delay of progression
of knee osteoarthritis: a 3-year, randomized, placebo-
controlled, double-blind study. Arch Intern Med 2002;162:
2113e23.
5. Kahan A, Uebelhart D, De VF, Delmas PD, Reginster JY. Long-
term effects of chondroitins 4 and 6 sulfate on knee osteoar-
thritis: the study on osteoarthritis progression prevention, a
two-year, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum 2009;60:524e33.for an update of the 2010 European regulatory guideline on clinical
tis and reflections about related clinically relevant outcomes: expert
rg/10.1016/j.joca.2015.07.001
J.-Y. Reginster et al. / Osteoarthritis and Cartilage xxx (2015) 1e8 76. CPMP. Points to Consider on Clinical Investigation of Medicinal
Products Used in Treatment of Osteoarthritis 1998. EMEA
[CPMP/EWP/748/97-London].
7. European Agency for the Evaluation of Medicinal Products
(EMEA), Committee for Medicinal Products for Human Use
(CHMP), Committee for Proprietary Medicinal Products
(CPMP). Guideline on clinical investigation of medicinal
products used in the treatment of osteoarthritis. -14. 20-1-
2010. London. Guideline on clinical investigation of medicinal
products used in the treatment of osteoarthritis.
8. Dougados M. Recommendations for the registration of drugs
used in the treatment of osteoarthritis. Group for the respect
of ethics and excellence in science (GREES): osteoarthritis
section. Ann Rheum Dis 1996;55:552e7.
9. Vignon E, Garnero P, Delmas P, Avouac B, Bettica P,
Boers M, et al. Recommendations for the registration of
drugs used in the treatment of osteoarthritis: an update on
biochemical markers. Osteoarthritis Cartilage 2001;9:
289e93.
10. Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O,
et al. Recommendations for the use of new methods to assess
the efficacy of disease-modifying drugs in the treatment of
osteoarthritis. Osteoarthritis Cartilage 2004;12:263e8.
11. Altman RD, Abadie E, Avouac B, Bouvenot G, Branco J,
Bruyere O, et al. Total joint replacement of hip or knee as an
outcome measure for structure modifying trials in osteoar-
thritis. Osteoarthritis Cartilage 2005;13:13e9.
12. Baerwald C, Verdecchia P, Duquesroix B, Frayssinet H,
Ferreira T. Efficacy, safety, and effects on blood pressure of
naproxcinod 750 mg twice daily compared with placebo and
naproxen 500 mg twice daily in patients with osteoarthritis of
the hip: a randomized, double-blind, parallel-group, multi-
center study. Arthritis Rheum 2010;62:3635e44.
13. Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V,
Belenkov Y, et al. A double-blind, randomized, placebo-
controlled study of the efficacy and safety of duloxetine for
the treatment of chronic pain due to osteoarthritis of the knee.
Pain Pract 2011;11:33e41.
14. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G,
McGowan J, et al. American College of Rheumatology 2012
recommendations for the use of nonpharmacologic and
pharmacologic therapies in osteoarthritis of the hand, hip, and
knee. Arthritis Care Res (Hoboken) 2012;64:455e74.
15. Rother M, Conaghan PG. A randomized, double-blind, phase III
trial in moderate osteoarthritis knee pain comparing topical
ketoprofen gel with ketoprofen-free gel. J Rheumatol 2013;40:
1742e8.
16. Schnitzer TJ, Kivitz A, Frayssinet H, Duquesroix B. Efficacy and
safety of naproxcinod in the treatment of patients with oste-
oarthritis of the knee: a 13-week prospective, randomized,
multicenter study. Osteoarthritis Cartilage 2010;18:629e39.
17. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal
anti-inflammatory drugs, including cyclo-oxygenase-2 in-
hibitors, in osteoarthritic knee pain: meta-analysis of rando-
mised placebo controlled trials. BMJ 2004;329:1317.
18. Tannenbaum H, Berenbaum F, Reginster JY, Zacher J,
Robinson J, Poor G, et al. Lumiracoxib is effective in the
treatment of osteoarthritis of the knee: a 13 week, rando-
mised, double blind study versus placebo and celecoxib. Ann
Rheum Dis 2004;63:1419e26.
19. Berenbaum F, Grifka J, Brown JP, Zacher J, Moore A,
Krammer G, et al. Efficacy of lumiracoxib in osteoarthritis: a
review of nine studies. J Int Med Res 2005;33:21e41.
20. Bjordal JM, Klovning A, Ljunggren AE, Slordal L. Short-term
efficacy of pharmacotherapeutic interventions in osteoarthriticPlease cite this article in press as: Reginster J-Y, et al., Recommendations
investigation of medicinal products used in the treatment of osteoarthri
consensus statement, Osteoarthritis and Cartilage (2015), http://dx.doi.orknee pain: a meta-analysis of randomised placebo-controlled
trials. Eur J Pain 2007;11:125e38.
21. Abhishek A, Doherty M. Mechanisms of the placebo response
in pain in osteoarthritis. Osteoarthritis Cartilage 2013;21:
1229e35.
22. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The
placebo effect and its determinants in osteoarthritis: meta-
analysis of randomised controlled trials. Ann Rheum Dis
2008;67:1716e23.
23. Bijlsma JW, Welsing PM. The art of medicine in treating
osteoarthritis: I will please. Ann Rheum Dis 2008;67:
1653e5.
24. Bellamy N, BuchananWW, Goldsmith CH, Campbell J, Stitt LW.
Validation study of WOMAC: a health status instrument for
measuring clinically important patient relevant outcomes to
antirheumatic drug therapy in patients with osteoarthritis of
the hip or knee. J Rheumatol 1988;15:1833e40.
25. Ehrich EW, Davies GM,Watson DJ, Bolognese JA, Seidenberg BC,
Bellamy N. Minimal perceptible clinical improvement with the
Western Ontario and McMaster Universities osteoarthritis in-
dex questionnaire and global assessments in patients with
osteoarthritis. J Rheumatol 2000;27:2635e41.
26. Cooper C, Adachi JD, Bardin T, Berenbaum F, Flamion B,
Jonsson H, et al. How to define responders in osteoarthritis.
Curr Med Res Opin 2013;29:719e29.
27. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N,
et al. Evaluation of clinically relevant changes in patient re-
ported outcomes in knee and hip osteoarthritis: the minimal
clinically important improvement. Ann Rheum Dis 2005;64:
29e33.
28. Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N,
Bombardier C, et al. Minimum clinically important improve-
ment and patient acceptable symptom state in pain and
function in rheumatoid arthritis, ankylosing spondylitis,
chronic back pain, hand osteoarthritis, and hip and knee
osteoarthritis: results from a prospective multinational study.
Arthritis Care Res (Hoboken) 2012;64:1699e707.
29. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N,
et al. Evaluation of clinically relevant states in patient reported
outcomes in knee and hip osteoarthritis: the patient accept-
able symptom state. Ann Rheum Dis 2005;64:34e7.
30. Pham T, Van der Heijde D, Altman RD, Anderson JJ, Bellamy N,
Hochberg M, et al. OMERACT-OARSI initiative: osteoarthritis
Research Society International set of responder criteria for
osteoarthritis clinical trials revisited. Osteoarthritis Cartilage
2004;12:389e99.
31. Trijau S, Avouac J, Escalas C, Gossec L, Dougados M. Influence
of flare design on symptomatic efficacy of non-steroidal anti-
inflammatory drugs in osteoarthritis: a meta-analysis of ran-
domized placebo-controlled trials. Osteoarthritis Cartilage
2010;18:1012e8.
32. Wise BL, Felson DT, Clancy M, Niu J, Neogi T, Lane NE, et al.
Consistency of knee pain and risk of knee replacement: the
Multicenter Osteoarthritis Study. J Rheumatol 2011;38:
1390e5.
33. Manno RL, Bingham III CO, Paternotte S, Gossec L, Halhol H,
Giacovelli G, et al. OARSI-OMERACT initiative: defining
thresholds for symptomatic severity and structural changes in
disease modifying osteoarthritis drug (DMOAD) clinical trials.
Osteoarthritis Cartilage 2012;20:93e101.
34. European Medicines Agency, Committee for Medicinal Prod-
ucts for Human Use (CHMP). Points to consider on multiplicity
issues in clinical trials. 19-9-2002.
35. Dougados M. Symptomatic slow-acting drugs for osteoar-
thritis: what are the facts? Joint Bone Spine 2006;73:606e9.for an update of the 2010 European regulatory guideline on clinical
tis and reflections about related clinically relevant outcomes: expert
g/10.1016/j.joca.2015.07.001
J.-Y. Reginster et al. / Osteoarthritis and Cartilage xxx (2015) 1e8836. Bruyere O, Burlet N, Delmas PD, Rizzoli R, Cooper C,
Reginster JY. Evaluation of symptomatic slow-acting drugs in
osteoarthritis using the GRADE system. BMC Musculoskelet
Disord 2008;9:165.
37. Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K,
Mullner M. Intra-articular hyaluronic acid for the treatment of
osteoarthritis of the knee: systematic review and meta-anal-
ysis. CMAJ 2005;172:1039e43.
38. Fidelix TS,MacedoCR,Maxwell LJ, FernandesMTV.Diacerein for
osteoarthritis. Cochrane Database Syst Rev 2014;2. CD005117.
39. Maheu E, Mazieres B, Valat JP, Loyau G, Le LX, Bourgeois P,
et al. Symptomatic efficacy of avocado/soybean unsaponifi-
ables in the treatment of osteoarthritis of the knee and hip: a
prospective, randomized, double-blind, placebo-controlled,
multicenter clinical trial with a six-month treatment period
and a two-month followup demonstrating a persistent effect.
Arthritis Rheum 1998;41:81e91.
40. Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the
treatment of osteoarthritis of the hip. Arthritis Rheum
1994;37:529e36.
41. Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U,
et al. Meta-analysis: chondroitin for osteoarthritis of the knee
or hip. Ann Intern Med 2007;146:580e90.
42. Herrero-Beaumont G, Ivorra JA, Del Carmen TM, Blanco FJ,
Benito P, Martin-Mola E, et al. Glucosamine sulfate in the
treatment of knee osteoarthritis symptoms: a randomized,
double-blind, placebo-controlled study using acetaminophen
as a side comparator. Arthritis Rheum 2007;56:555e67.
43. FDA Draft Guidance. Clinical Development Programs for Drugs,
Devices and Biological Products Intended for the Treatment of
OA 1999. Federal Register 64[135].
44. Bruyere O, Richy F, Reginster JY. Three year joint space nar-
rowing predicts long term incidence of knee surgery in pa-
tients with osteoarthritis: an eight year prospective follow up
study. Ann Rheum Dis 2005;64:1727e30.
45. Bruyere O, Cooper C, Pavelka K, Rabenda V, Buckinx F,
Beaudart C, et al. Changes in structure and symptoms in knee
osteoarthritis and prediction of future knee replacement over
8 years. Calcif Tissue Int 2013;93:502e7.
46. Mazzuca SA, Brandt KD. Plain radiography as an outcome
measure in clinical trials involving patients with knee osteo-
arthritis. Rheum Dis Clin North Am 1999;25:467e80. ix.Please cite this article in press as: Reginster J-Y, et al., Recommendations
investigation of medicinal products used in the treatment of osteoarthri
consensus statement, Osteoarthritis and Cartilage (2015), http://dx.doi.o47. Brandt KD, Mazzuca SA. Lessons learned from nine clinical
trials of disease-modifying osteoarthritis drugs. Arthritis
Rheum 2005;52:3349e59.
48. Ornetti P, Brandt K, Hellio-le Graverand MP, Hochberg M,
Hunter DJ, Kloppenburg M, et al. OARSI-OMERACT definition of
relevant radiological progression in hip/knee osteoarthritis.
Osteoarthritis Cartilage 2009;17:842e9.
49. Reginster JY, Badurski J, Bellamy N, Bensen W, Chapurlat R,
Chevalier X, et al. Efficacy and safety of strontium ranelate in
the treatment of knee osteoarthritis: results of a double-blind,
randomised placebo-controlled trial. Ann Rheum Dis 2013;72:
179e86.
50. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham III CO,
Harris CL, et al. The effect of glucosamine and/or chondroitin
sulfate on the progression of knee osteoarthritis: a report from
the glucosamine/chondroitin arthritis intervention trial.
Arthritis Rheum 2008;58:3183e91.
51. Pham T, Le HA, Ravaud P, Dieppe P, Paolozzi L, Dougados M.
Evaluation of the symptomatic and structural efficacy of a new
hyaluronic acid compound, NRD101, in comparison with
diacerein and placebo in a 1 year randomised controlled study
in symptomatic knee osteoarthritis. Ann Rheum Dis 2004;63:
1611e7.
52. Maheu E, Cadet C, Marty M, Moyse D, Kerloch I, Coste P, et al.
Randomised, controlled trial of avocado-soybean unsaponifi-
able (Piascledine) effect on structure modification in hip
osteoarthritis: the ERADIAS study. Ann Rheum Dis 2014;73:
376e84.
53. Michel BA, Stucki G, Frey D, De VF, Vignon E, Bruehlmann P,
et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee:
a randomized, controlled trial. Arthritis Rheum 2005;52:
779e86.
54. Bruyere O, Pavelka K, Rovati LC, Gatterova J, Giacovelli G,
Olejarova M, et al. Total joint replacement after glucosamine
sulphate treatment in knee osteoarthritis: results of a mean 8-
year observation of patients from two previous 3-year, rand-
omised, placebo-controlled trials. Osteoarthritis Cartilage
2008;16:254e60.
55. Hunter DJ, Nevitt M, Losina E, Kraus V. Biomarkers for osteo-
arthritis: current position and steps towards further valida-
tion. Best Pract Res Clin Rheumatol 2014;28:61e71.for an update of the 2010 European regulatory guideline on clinical
tis and reflections about related clinically relevant outcomes: expert
rg/10.1016/j.joca.2015.07.001
